Miguel Lanz, MD
Allergy · Coral Gables, FLNPI 1710034129
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by AstraZeneca at 40.0% of the total. 2025 is the largest year on record at $196,802, 3.3 times the $59,295 reported in 2019. Among allergy clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 973 payments — averaging $799.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$311K
- Sanofi$264K
- Regeneron Healthcare Solutions, Inc.$102K
- Optinose US, Inc.$20K
- Astrazeneca UK Limited$19K
- Amgen$14K
- plus $49K from 19 others
Across 363 payments — averaging $2341.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$321K
- Regeneron$289K
- AstraZeneca$154K
- Optinose US, Inc.$78K
- Novartis$9K
What the payments were for
- Consulting fees$214,42528%
- Speaking & faculty fees$454,30158%
- Travel & lodging$76,99010%
- Food & beverage$31,9254%
- Education$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 347 | $311,253 |
| Sanofi | 264 | $263,517 |
| Regeneron Healthcare Solutions, Inc. | 142 | $102,021 |
| Optinose US, Inc. | 25 | $19,702 |
| Astrazeneca UK Limited | 14 | $18,721 |
| Amgen | 13 | $13,748 |
| Regeneron | 31 | $13,221 |
| Novartis | 29 | $11,230 |
| Genentech USA, Inc. | 16 | $7,160 |
| Grifols USA, LLC | 9 | $5,927 |
| Alk-abello, Inc | 19 | $3,275 |
| Chiesi USA, Inc. | 2 | $2,289 |
| Astrazeneca AB | 10 | $1,459 |
| Blueprint Medicines Corporation | 1 | $1,260 |
| Sanofi-aventis U.S. LLC | 15 | $1,124 |
| Genentech, Inc. | 15 | $1,042 |
| GSK | 9 | $340 |
| Galderma Laboratories, L.p. | 1 | $135 |
| Circassia Inc. | 2 | $125 |
| Lilly USA, LLC | 2 | $76 |
| Greer Laboratories, Inc. | 1 | $72 |
| Pfizer | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 1 | $42 |
| Merck | 2 | $34 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$777,852 in reported general payments places this provider in the 95th percentile of 56 allergy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy in Coral Gables
- Brett StanalandNaples$575K
- David RoseEglin Afb$253K
- Pavana BeerelliRockledge$61K
- Hugh WindomSarasota$37K
- Patrick de MarcoOrange Park$23K
- Mark MinorMelbourne$21K
- Alan KoterbaNorth Palm Beach$16K
- Brian WilsonTallahassee$11K
- Sanjay SwamiJacksonville$11K
- Latha ChamarthyPinellas Park$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.